Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / Rahman 9-marker MALDI MS panel for Lung Cancer

Rahman 9-marker MALDI MS panel for Lung Cancer



QA State: Curated
Short Name:
HGNC Name:

This panel was derived from the proteomic analysis of bronchial lesions that could predict the diagnosis of lung cancer. Nine matrix-assisted laser desorption ionization mass spectrometry (MALDI MS) mass to charge ratio features were selected to build a prediction model diagnostic of lung cancer. One signature was not able to be associated with a particular protein. The remaining eight signatures are derived from: Thymosin beta-4 (TMSB4X), Macrophage migration inhibitory factor (MIF), Des-ubiquitin (Ubiquitin-Gly-Gly), Ubiquitin, Acyl-coA binding protein (ACBP, also known as DBI), Cystatin A (CSTA), and Cytochrome c.

Panel Details


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Curated


Determining the probability of having lung cancer based on a novel proteomic signature of bronchial lesions may have important clinical implications. This signature may facilitate the diagnosis of lung cancer and the monitoring of high-risk individuals for lung cancer in surveillance and chemoprevention trials.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.


No associated resources found.

2015 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place January 20–21, 2016 in Bethesda, Maryland.

Announcement 08/26/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Wednesday-Thursday, January 20-21, 2016, on the NCI campus. More information will be available later this summer.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.